Journal of Clinical Immunology

, Volume 33, Issue 2, pp 489–495 | Cite as

Diagnostic and Prognostic Value of Low Density Lipoprotein-Containing Circulating Immune Complexes in Atherosclerosis

  • Igor A. Sobenin
  • Vasily P. Karagodin
  • Alexandra А. Melnichenko
  • Yuri V. Bobryshev
  • Alexander N. Orekhov
Original Research


Recently, it has been shown that increased level of LDL-containing circulating immune complexes (LDL-CIC) possess high diagnostic significance in clinically manifested atherosclerosis, but little is known about its diagnostic and prognostic significance in early atherosclerosis. Two-years prospective study was performed in 98 asymptomatic men aged 40–74. The rate of atherosclerosis progression was estimated by high-resolution B-mode ultrasonography as the increase in intima-media thickness (IMT) of common carotid arteries. The patients with elevated baseline levels of LDL-CIC were characterized by significantly higher levels of total and LDL cholesterol as well as significantly increased mean IMT of common carotid arteries. Among all baseline lipid parameters, only LDL-CIC and LDL cholesterol were contingent with the extent of early carotid atherosclerosis (p = 0.042 and p = 0.049, respectively) and had the highest levels of relative risk and odds ratio. During the follow up, significant IMT increase was registered in 53.1 % (n = 52) patients, IMT significant reduction was observed in 21.4 % (n = 21) patients. The increased levels of LDL-CIC, total serum cholesterol and LDL cholesterol had similar prognostic significance with the respect of atherosclerosis progression. The normal level of LDL-CIC (below than 16.0 μg/ml) was the only lipid parameter that predicted the absence of carotid atherosclerosis progression for two following years at prognostic value of 78.3 %. The results of the study allow assuming that LDL-CIC level may be employed not only as a marker of early atherosclerosis, but also has a sufficient prognostic value for clinical implications.


Atherosclerosis carotid arteries imaging immunology lipoproteins 



We thank Maria V. Razumkina for assistance with statistical analysis.


The study was supported by the Russian Ministry of Education and Science.

Conflict of Interest

There are no conflicts of interest related to the manuscript.


All authors have contributed in a substantive and intellectual manner to the work described.

Supplementary material

10875_2012_9819_MOESM1_ESM.docx (90 kb)
Supplementary Figure 1 Correlation plots of carotid IMT and lipid parameters at the baseline. A—total cholesterol, B—LDL cholesterol, C—HDL cholesterol, D—triglycerides, E—LDL-CIC. (DOCX 89 kb)
10875_2012_9819_MOESM2_ESM.docx (90 kb)
Supplementary Figure 2 Correlation plots of changes in carotid IMT during follow-up and baseline lipid parameters. A—total cholesterol, B—LDL cholesterol, C—HDL cholesterol, D—triglycerides, E—LDL-CIC. (DOCX 90 kb)
10875_2012_9819_MOESM3_ESM.docx (104 kb)
Supplementary Figure 3 ROC curves for sensitivity/specificity analysis of lipid parameters. 1—LDL-CIC, 2—LDL cholesterol, 3—HDL cholesterol, 4—total cholesterol, 5—triglycerides. For LDL-CIC, LDL cholesterol, total cholesterol and triglycerides IMT progression is taken as an actual state; for HDL cholesterol the absence of IMT progression is taken as an actual state. Diagonal segments are produced by ties. (DOCX 104 kb)


  1. 1.
    Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.PubMedCrossRefGoogle Scholar
  2. 2.
    Orekhov AN, Tertov VV, Novikov ID, et al. Lipids in cells of atherosclerotic and uninvolved human aorta. I. Lipid composition of aortic tissue and enzyme-isolated and cultured cells. Exp Mol Pathol. 1985;42:117–37.PubMedCrossRefGoogle Scholar
  3. 3.
    Tertov VV, Orekhov AN, Sayadyan KS, et al. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients’ serum manifested in cell culture. Atherosclerosis. 1990;81:183–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol. 1990;52:300–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Gisinger C, Virella GT, Lopes-Virella MF. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopathol. 1991;59:37–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Kacharava AG, Tertov VV, Orekhov A. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med. 1993;25:551–5.PubMedGoogle Scholar
  7. 7.
    Virella G, Lopes-Virella MF. Humoral immunity and atherosclerosis. Nat Med. 2003;9:243–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 1997;135:161–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Tertov VV, Orekhov AN, Ryong LH, Smirnov VN. Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cells. Tissue Cell. 1988;20:849–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Orekhov AN, Tertov VV, Kudryashov SA, Smirnov VN. Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res. 1990;66:311–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Orekhov AN, Kalenich OS, Tertov VV, Perova NV, Novikov ID, Lyakishev AA, Deev AD, Ruda MY. Diagnostic value of immune cholesterol as a marker for atherosclerosis. J Cardiovasc Risk. 1995;2:459–66.PubMedCrossRefGoogle Scholar
  12. 12.
    Orekhov AN, Kalenich OS, Tertov VV, Novikov ID. Lipoprotein immune complexes as markers of atherosclerosis. Int J Tissue React. 1991;13:233–6.PubMedGoogle Scholar
  13. 13.
    Tertov VV, Sobenin IA, Orekhov AN, Jaakkola O, Solakivi T, Nikkari T. Characteristics of low density lipoprotein isolated from circulating immune complexes. Atherosclerosis. 1996;122:191–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758–64.PubMedCrossRefGoogle Scholar
  15. 15.
    Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol. 1989;135:815–25.PubMedGoogle Scholar
  17. 17.
    Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086–95.PubMedCrossRefGoogle Scholar
  18. 18.
    Hollander W, Colombo MA, Kirkpatrick B, Paddock J. Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin. Atherosclerosis. 1979;34:391–405.PubMedCrossRefGoogle Scholar
  19. 19.
    Hansson GK, Bondjers G, Bylock A, Hjalmarsson L. Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits. Exp Mol Pathol. 1980;33:302–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Parums D, Mitchinson MJ. Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. Atherosclerosis. 1981;38:211–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 1985;55:35–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Szondy E, Horváth M, Mezey Z, Székely J, Lengyel E, Füst G, Gerö S. Free and complexed anti-lipoprotein antibodies in vascular diseases. Atherosclerosis. 1983;49:69–77.PubMedCrossRefGoogle Scholar
  23. 23.
    Beaumont JL, Vivier P. Circulating IgA-Lp complexes in Watanabe heritable hyperlipidemic and cholesterol fed NZW rabbits. Atherosclerosis. 1990;82:227–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Orekhov AN, Tertov VV, Kabakov AE, Adamova IY, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb. 1991;11:316–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Klimov AN, Denisenko AD, Vinogradov AG, Nagornev VA, Pivovarova YI, Sitnikova OD, Pleskov VM. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis. 1988;74:41–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006;37:208–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Orekhov AN, Andreeva ER, Andrianova IV, Bobryshev YV. Peculiarities of cell composition and cell proliferation in different type atherosclerotic lesions in carotid and coronary arteries. Atherosclerosis. 2010;212:436–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Beaumont JL, Doucet F, Vivier P, Antonucci M. Immunoglobulin-bound lipoproteins (Ig-Lp) as markers of familial hypercholesterolemia, xanthomatosis and atherosclerosis. Atherosclerosis. 1988;74:191–201.PubMedCrossRefGoogle Scholar
  31. 31.
    Simon A, Giral P, Levenson J. Extracoronary atherosclerotic plaque at multiple sites and total coronary calcification deposit in asymptomatic men. Association with coronary risk profile. Circulation. 1995;92:1414–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G. DCCT/EDIC Research Group. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007;190:359–69.PubMedCrossRefGoogle Scholar
  33. 33.
    Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Diabetes. 2011;60:582–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Igor A. Sobenin
    • 1
    • 2
  • Vasily P. Karagodin
    • 1
  • Alexandra А. Melnichenko
    • 2
  • Yuri V. Bobryshev
    • 2
    • 3
  • Alexander N. Orekhov
    • 1
    • 2
  1. 1.Institute of General Pathology and PathophysiologyRussian Academy of Medical SciencesMoscowRussia
  2. 2.Institute for Atherosclerosis ResearchSkolkovo Innovative CentreMoscow RegionRussia
  3. 3.Faculty of MedicineSt Vincent’s Hospital Sydney and University of New South WalesKensingtonAustralia

Personalised recommendations